October 30, 2025 — Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company focused on RNA medicine, will host a webcast and conference call on November 4, 2025, at 4:30 p.m. ET to discuss third quarter 2025 business and financial updates. The company’s lead investigational medicine, zorevunersen, is in development as a potential treatment for Dravet syndrome.
The webcast will be available on Stoke’s website. Research analysts can register to join the call and Q&A session. A replay will be available for at least 90 days.
Stoke Therapeutics (Nasdaq: STOK) is dedicated to restoring protein expression through RNA medicine, using its proprietary TANGO approach to develop antisense oligonucleotides (ASOs). The company’s first medicine, zorevunersen, is being evaluated in a Phase 3 study for Dravet syndrome. Stoke is focused on diseases of the central nervous system and the eye caused by a loss of ~50% of normal protein levels (haploinsufficiency). Stoke is headquartered in Bedford, Massachusetts.
Source: Stoke Therapeutics
